Farnesoid X receptor (FXR) belongs to the nuclear receptor superfamily with its endogenous ligands bile acids. Mice with whole-body FXR deficiency develop liver tumors spontaneously, but the underlying mechanism is unclear. Moreover, it is unknown whether FXR deficiency in liver alone serves as a tumor initiator or promoter during liver carcinogenesis. this study aims to evaluate the effects of hepatocytespecific FXR deficiency (FXR mouse livers increased basal expression of tumor suppressor p53 protein, apoptosis and decreased basal cyclin D1 expression, which may prevent tumor development in FXR hep-/-mice. However, cholic-acid feeding reversed these effects in FXR hep-/-mice, which is associated with an increased cyclin D1 and decreased cell cycle inhibitors. More in-depth analysis indicates that the increased in cell growth might be resulted from disturbance of the MAPK and JAK/STAT3 signaling pathways. In conclusion, this study shows that hepatic FXR deficiency may only serve as a tumor initiator and increased bile acids is required for tumor formation likely by promoting cell proliferation.
Introduction
Farnesoid X receptor (FXR) is a ligand-activated nuclear receptor, and is highly expressed in the liver, intestine, kidney, and adrenals. The endogenous ligands of FXR are bile acids, including primary and secondary bile acids (15, 18, 24) . FXR is essential in maintaining bile acid homeostasis, and FXR deficiency has been involved in the pathogenesis of a variety of liver and intestinal diseases. Particularly, FXR serves as a tumor suppressor in the liver and colon, and this emerging concept has been strongly supported by a few studies conducted in whole-body FXR knockout mice demonstrating that FXR deficiency leads to spontaneous liver tumor development and increased colon cancer susceptibility; furthermore, the expression and function of FXR was found to be reduced in human liver tumors and colon cancers, indicating a strong link between FXR deficiency and human hepatic and colon cancer development (7, 25, 26, 28) . However, the mechanisms by which FXR deficiency results in tumor development are not clear. Whole-body FXR deficiency elevates bile acid levels and increased bile acids are known to promote tumor development in several carcinogenesis models, including liver and colon cancers (2, 8, 23) . However, it is unknown whether liver-specific FXR deficiency serves as a tumor initiator as well, in addition to promoting liver tumor development via increasing bile acid levels. This is because, for the last few years, we and others have identified that FXR likely suppresses tumor development via direct and indirect pathways. In detail, FXR directly serves as a transcription factor to induce the gene expression of several tumor suppressors, including small heterodimer partner (Shp), E-cadherin, and SOCS3, which are mediators critical in suppressing cell cycle proliferation, β-catenin activation and STAT3 activation, respectively (13, 14, 27, 32) . Indirectly, FXR activation prevents overt bile acid levels, and increased bile acids have been shown to lead to increased inflammation, IL-6 production, STAT3 activation, and β-catenin activation (13, 14, 27) . Therefore, there is an urgent need to develop an experimental model to test to what degree that specific FXR deficiency in the liver causes liver tumor via direct tumor initiation and/or promotion. This knowledge will help to better design strategies in the future to prevent and/or treat liver tumors associated with FXR mal-function/deficiency.
Thereby, in the current study, we used hepatocyte-specific FXR KO mice (FXR hep-/-) to determine to what degree hepatocyte-specific FXR deficiency is a tumor initiator and/or promoter in vivo. In detail, the role of FXR deficiency in hepatocytes as either tumor initiator and/or promoter was tested using four groups of mice: role as both initiator and promoter (mice without chemical treatment ---spontaneous tumor development), role as tumor initiator (mice with bile acid treatment as promoter ---dietary supplement of lowdose cholic acid; CA; 0.2%), role as tumor promoter (mice with prior tumor initiation with diethylnitrosamine ---DEN), and no effects on liver tumor development (mice treated with both DEN and CA) (20) .
Material and Methods

Animals and treatments
FXR hepatocyte-specific knockout mice (FXR hep-/-) have been described previously (9 Male WT and FXR hep-/-mice (n = 4-10) were treated with a single intraperitoneal (i.p.) injection of N,N-diethylnitrosamine (DEN) at 90 mg/kg or PBS vehicle at 4 weeks of age, followed by feeding with 0.2% (w/w) CA-containing diet or regular chow diet for 30 weeks. Liver tissues were harvested to determine mRNA and protein levels.
Serum biochemistry
Serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities along with triglyceride, total cholesterol and total bilirubin levels were determined using commercially available kits (Pointe Scientific, Canton, MI). Serum total bile acids were measured using a bile acid assay kit according to the manufacturer's instructions (BioQuant, San Diego, CA).
Liver histology
When livers were collected, pieces of liver were fixed in 10% neutral buffered formalin solution and embedded in paraffin. 5-μm-thick sections were obtained for hematoxylin and eosin (H&E) staining. The pathological analysis and diagnosis was provided by a board-certified pathologist.
RNA isolation and quantitative real-time PCR (Q-PCR)
Total RNA was isolated from frozen livers by TRIzol reagent. The mRNA expression levels of genes were quantified by Q-PCR using SYBR green chemistry and normalized to β-actin mRNA levels. A list of genes and primers are in supporting data Table 1 .
Western blot analysis
Western blot analysis was performed as previously described on total, nuclear and cytoplasmic proteins (9) . Antibodies are described in supporting data Table 2 .
Organic Extraction and Ultra Performance Liquid Chromatography/Mass Spectrometry (UPLC/MS) Profiling of Liver Bile Acids
Three-month-old male mice (n=5) were used to determine the bile acid profile. Total Bile acids were extracted from serum, liver, gall bladder and intestine contents using a method described before (31, 33 (31) . Full names of all the 23 bile acids are described in a previous published paper (31) . The proportion of each individual bile acid in the total liver bile acid or total bile acid pool were calculated.
Statistical analysis
Results were presented as means ± SD, and were analyzed by one-way ANOVA followed by the Student-Newman-Keuls test. A difference with a P value of < 0.05 was considered statistically significant.
Results
Tumor prevalence. Liver Histology. As shown in Table 2 and showed focal portal inflammation, which we did not see in any of the WT mice. After CA treatment, 29% (2 out of 7) of WT mice presented with high-grade dysplasia, but they did not show any signs of focal portal inflammation. In contrast, the CA treatment resulted in 87% dysplasia in FXR hep-/-mice with 27% low-grade and 60% high-grade dysplasia, and 27% focal portal inflammation. With DEN treatment only, none of the WT mice developed dysplasia or portal inflammation, while 29% of FXR hep-/-mice developed low-grade dysplasia and 57% showed focal portal inflammation. For DEN/CA treatment, all WT mice presented with high-grade dysplasia, none with low-grade dysplasia, and 33% with focal portal inflammation; and for FXR hep-/-mice, 57% showed high-grade dysplasia, 43% low-grade dysplasia, and 14%focal portal inflammation.
The body weight was increased in WT mice with CA feeding (Fig. 1C) reflected by a marked increase in bilirubin levels (Fig. 2) .
Expression of genes involved in bile acid homeostasis in the liver. Fig. 3 Treatment with CA markedly suppressed Cyp7a1 mRNA levels, but the degree of suppression was smaller in FXR hep-/-mice than in WT mice.
Cell proliferation and death. Fig. 4 shows the protein levels of genes critical for cell proliferation and cell apoptosis, including cyclin D1, cdk4, cyclin E1, cdk2, PCNA, PARP1, and caspase 3. The basal levels of cyclin D1 were lower in WT mice and almost undetectable in FXR hep-/-mice, consistent with our previous finding that cyclin D1
is a FXR target gene in the liver (1, 22) . The cyclin D1 levels were slightly higher in WT mice after CA treatment, but markedly higher in the FXR hep-/-mice, suggesting that cyclin D1 is induced via-FXR independent mechanism(s). Cyclin D1 levels were slightly reduced in WT mice by DEN treatment, but markedly induced in both strains by the combined DEN/CA treatment. These data suggest that cyclin D1 induction may serve as a marker for tumor development in this study. Interestingly, the trend of change for cyclin E1 was opposite of that of cyclin D1. Furthermore, despite reduced basal cyclin D1 in FXR hep-/-mice, the levels of its partner, cdk4, were higher (perhaps to compensate for the loss of cyclin D1). Activation of MAPK pathway. Increased bile acids are known to activate MAPK signaling pathways, especially via activation of JNK and ERK (5, 19) . However, in our study, we found that the total JNK1/2 levels were not changed in these groups, but the p-JNK1/2 levels were markedly reduced by CA and/or DEN treatments (Fig.6) . Even though the total bile acid levels were not increased by hepatocyte-specific deletion of FXR, the FXR hep-/-mice had increased total and phosphorylated cJun, which was, surprisingly reduced by CA and/or DEN treatment (Fig. 6) . CA treatment increased pErk1 in FXR hep-/-mice and DEN/CA increased p-Erk1 in both strains. The results suggest that long-term bile acid treatment may desensitize MAPK activation to some degree, and levels of T-or p-cJun were negatively, while the levels of p-Erk1 were positively, correlated with liver tumor formation in this study.
Activation of Stat3 pathway.
Stat3 activation has been demonstrated to promote cell cycle progression and tumorigenesis by increasing the gene transcription of genes involved in pro-survival and pro-inflammatory pathways (3, 6, 30) . Our previous study also indicates that constitutive activation of STAT3 may be involved in tumorigenesis in liver of FXR whole-body knockout mice (14) . Here we further examined activation of the Stat3 pathway in FXR hep-/-mice (Fig. 7) . The FXR hep-/-mice appeared to have higher Stat3 activation, suggested by increased GP130, JAK1, JAK2, p-and total-stat3, and decreased Socs3. This result is consistent with our previous report that there was a FXR/Socs3/Stat3 regulatory loop by which FXR positively induces Socs3 to suppress Stat3 activation (14) . In the FXR whole-body KO mice, p-Stat3 was increased at both Y705 and S727, however, in the current study, both CA and DEN treatment resulted in down-regulation of total and p-Stat3 (Y705) protein levels, while p-Stat3 (S727) protein levels were increased. This differential phosphorylation of Stat3 protein in FXR wholebody KO and FXR hep-/-mice suggests a more complicated regulation of Stat3 activation by FXR deficiency and increased bile acid concentration.
Altered Liver Bile Acids Profiles in FXR Knockout
Mice. The gathered data shown in this study indicate that hepatic FXR serves a cytoprotective role during the initiation stage of carcinogenesis. As the master regulator of bile acid homeostasis, FXR regulates the synthesis and transport of bile acids. Moreover, the alteration in bile acid pool and composition could play a role in the tumorigenesis, especially tumor promotion. The total bile acid pool size has also been published by us previously, showing that bile acid pool size was only slightly increased in FXR hep-/-mice comparing to WT mice (9) . The liver bile-acid composition and bile acid pool were measured in the current study by the UPLC/MS method (Fig. 8) . Levels of four bile acids (GDCA, LCA, GUDCA and T-ω-MCA) were below the UPLC-MS detection limits among 23 bile acids measured. For bile acids that have relatively higher concentration in the liver (Fig. 8A , left panel) and compared to WT mice, the relative percentage of β-MCA and ω-MCA in the liver was increased significantly in FXR KO and FXR hep-/-mice. Among the bile acids that have relatively lower concentration in the liver, CDCA, α-MCA and HDCA were also significantly higher in FXR hep-/-mice (Fig. 8A, right panel) . In the total bile acid pool, the individual bile acid composition was similar to that in the liver (Fig. 8B) . Overall, the levels of ω-MCA, DCA, CDCA and α-MCA were significantly increased in FXR hep-/-mice, while HDCA and β-MCA also showed a slight increase in these mice compared to WT mice.
Discussion
The bile acid activated nuclear receptor, FXR, is known to suppress HCC and colon cancer development, and particularly, whole-body FXR deficiency in mice leads to spontaneous liver tumor development (7, 16, 27, 28) . However, the mechanism by which FXR suppresses carcinogenesis is not entirely clear. FXR is essential in maintaining bile acid homeostasis, and deletion of FXR in mice results in increased bile acids level in the body because of the increasing bile acid biosynthesis and altered transport. Bile acids is well-known for its tumor promotion effects, and has been found to promote carcinogenesis in several tumor models, including HCC, cholangiocarcinoma, colon cancer, and breast cancer. Consequently, the spontaneous liver tumorigenesis in FXR KO mice can be resulted from the direct effects of loss of FXR-dependent protection, and/or the increased bile-acid toxicity. Recent study shows that whole body FXR knockout mice with intestine-specific FXR overexpression could prevent the spontaneous hepatocarcinogenesis (4), likely due to the re-establishment of suppression of Cyp7a1 expression with the intact intestinal FXR/FGF15 signal to reduce bile-acid levels. Another study had been conducted on an intestinal tumorigenesis model of FXR KO/Apc Min+ mice, which showed that reducing bile-acid levels with bile acid binding resin, cholestyramine, did not modify the intestinal tumor susceptibility of FXR -/-mice (17) . All these studies indicate that not only elevated bile acid concentrations increase susceptibility to tumorigenesis, loss of FXR was also involved, but the exact role of FXR as tumor initiator or promoter is not clear.
In this study, we used the hepatocyte-specific FXR knockout mice, which have serum bile acid levels comparable to those of WT mice, and determined the role of hepaticspecific deficiency of FXR as initiator and/or promoter in liver tumor development using the two-stage tumorigenesis model (DEN initiation/bile acid promotion) in hepatocytespecific FXR KO (FXR hep-/-) mice. This study highly suggests that FXR deficiency in hepatocytes likely serves as a tumor initiator. The current study clearly showed that FXR deficiency in hepatocytes did not result in spontaneous liver tumor development in mice, indicating that in contrast to whole-body FXR deficiency, hepatocyte-specific FXR deficiency is not sufficient for tumor development, i.e., FXR deficiency in hepatocytes is not a complete tumor initiator and promoter. The basal bile acid levels in the FXR hep-/-mice were comparable to those in WT mice, suggesting that additional injury due to elevated bile acids is likely required for tumorigenesis in the liver. We have measured the relative bile acid composition in the livers of WT, FXR KO, and FXR hep-/-mice, and found overall the bile acid composition among these three strains was similar, with the exception for a few bile acid species that were altered with whole-body FXR deficiency or hepatic FXR deficiency. Furthermore, the liver specific FXR deficiency only slightly altered the bile acid composition. For example, ω-MCA was higher in the FXR hep-/-mice.
The MCAs are found to be FXR antagonists than agonists, and this differential FXR modulating function may alter the homeostasis by which FXR maintains in vivo in mice (12, 21) . Indeed, the FXR hep-/-mice showed much higher tumor prevalence under chronic bile acid feeding, confirming that additional injury is required for liver tumorigenesis under hepatic FXR deficient conditions. Moreover, FXR deficiency is likely a tumor initiator rather than a promoter because treatment with the tumor initiator, DEN, did not render the FXR hep-/-mice more susceptible to tumor development. These results are in agreement with the earlier findings of others (4, 17) , indicating that liver tumorigenesis depends on both the initiation effects from loss of hepatic FXR function and tumor promotion from increased bile acids.
FXR deficiency increased liver injury in the DEN/CA model, as reflected by body weight loss, increased levels of liver enzymatic activities, bile acids and bilirubin. It is surprising that FXR hep-/-mice showed marked injury following bile acid feeding. Our previously studies suggest that the intestine serves is critical for regulating bile acid synthesis under physiological conditions (9) , but this study clearly indicates an important role of hepatic FXR in bile acid detoxification. We found that expression of Bsep was low in the Our lab and others have provided emerging evidence suggesting that FXR may directly suppress cell proliferation by inducing a few tumor suppressors (Shp, Socs3, and Ecadherin) and/or indirectly suppress cell proliferation by reducing bile acid levels as increased bile acids activate Stat3, MAPK, and β-catenin (13, 14, 27) , which are briefly summarized in Fig. 9 .
Interestingly, one of the central tumor suppressors, p53, was markedly induced in the FXR hep-/-mouse livers. The mechanism, for which we have hypothesized, is likely due to the reduction of Shp in FXR hep-/-mice. Shp is a classical FXR target gene in the liver and the reduction of p53 by Shp has been reported with the mechanism showing that Shp mediates the stabilization of mdm2, the protein that promotes p53 degradation (29, 32) . Furthermore, Shp has also been shown to inhibit p53 occupancy in its target genes (11) , therefore, the lack of Shp in FXR hep-/-mice could additionally enhance p53 transcriptional activity (Fig. 9) . But apparently, p53 is also regulated by mechanism(s) other than Shp, as bile acid feeding induced Shp in WT mice, which did not lead to a reduction of p53.
Hepatocarcinogenesis is a complicated and multistep process through differential mechanisms, and dysregulation of multiple signaling pathways is implicated in HCC carcinogenesis and progression, including the WNT/β-catenin, mitogen-activated protein kinase (MAPK), IL-6/STAT3 pathways etc.. This study also shows the paradoxical effects of FXR modulation on cell proliferation and regulation of the signaling pathways. We have reported that FXR directly induces several tumor suppressors, including Shp, E-cadherin, and Socs3, to suppress cell proliferation. In addition, FXR is well known to suppress bile acid levels and thus to inhibit bile acidinduced cell proliferation. In contrast, the current study showed reduced expression of Cyclin D1 in FXR hep-/-mice, which is in agreement with our previous report that FXR positively regulates Cyclin D1 gene expression (27) . The mechanism of increased p21 and p27 levels needs to be further determined, but likely could be due to indirect regulation with FXR deficiency.
In summary, this study clearly suggests that male mice with hepatocyte-specific FXR deficiency are resistant to spontaneous liver tumor formation, but may serve to initiate liver carcinogenesis, and increased bile acid levels, commonly observed in a variety of liver diseases, strongly leads to liver injury and promotes liver tumorigenesis under conditions of FXR deficiency. Increased bile acids have been considered as tumor promoting agents. As the master regulator of bile acid homeostasis, FXR induces BSEP to remove bile acids from the liver and thus helps to reduce bile-acid toxicity as well as suppressing bile acid synthesis. FXR may directly suppress cell proliferation by inducing a few tumor suppressors (including but may not limit to, Shp, Socs3, and E-cadherin) and/or indirectly suppress cell proliferation by reducing bile-acid levels as increased bile acids activate Stat3, MAPK, and β-catenin. In addition, FXR might also suppress liver p53 expression via its canonical target gene Shp. 
